Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GIMV
Biotech
European investment firm ends activity in the life sciences
The decision comes days after Gimv led a $60.6 million series B round for neuropsych biotech Exciva.
Darren Incorvaia
Jan 26, 2026 2:25pm
ImCheck checks off next funding round, refueling with some $101M
Jun 13, 2022 1:00am
Racing Sanofi, ImmunOs bags $74M for myeloid checkpoint trials
Jun 7, 2022 8:30am
Abingworth, Pfizer back $61M gene therapy delivery round
Sep 16, 2021 2:00am
Kinaset Therapeutics debuts with $40M for pan-JAK asthma med
Nov 30, 2020 7:00am
SynOx raises €37M to advance ex-Roche drug in rare tumor type
Nov 19, 2020 8:40am
